{"protocolSection":{"identificationModule":{"nctId":"NCT02535611","orgStudyIdInfo":{"id":"MAZUMS"},"organization":{"fullName":"Mazandaran University of Medical Sciences","class":"OTHER"},"briefTitle":"Evaluation of Memantine Versus Placebo on Ischemic Stroke Outcome","acronym":"EMISO"},"statusModule":{"statusVerifiedDate":"2020-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-10","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2016-10","type":"ACTUAL"},"completionDateStruct":{"date":"2017-09","type":"ACTUAL"},"studyFirstSubmitDate":"2015-08-22","studyFirstSubmitQcDate":"2015-08-27","studyFirstPostDateStruct":{"date":"2015-08-28","type":"ESTIMATED"},"resultsFirstSubmitDate":"2020-08-11","resultsFirstSubmitQcDate":"2020-08-27","resultsFirstPostDateStruct":{"date":"2020-09-16","type":"ACTUAL"},"lastUpdateSubmitDate":"2020-09-15","lastUpdatePostDateStruct":{"date":"2020-10-06","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Nasim Tabrizi","investigatorTitle":"Assistant professor of neurology","investigatorAffiliation":"Mazandaran University of Medical Sciences"},"leadSponsor":{"name":"Mazandaran University of Medical Sciences","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The researchers aim to investigate the effect of memantine on stroke outcome in a randomized double-blind placebo-controlled clinical trial."},"conditionsModule":{"conditions":["Ischemic Stroke","Excitotoxicity","Memantine"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":47,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Memantine","type":"ACTIVE_COMPARATOR","description":"Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive 20 mg/d(2 tab 5mg BID) memantine for 7 days and then 10mg/d(1 tab 5mg BID) memantine for 21 days.","interventionNames":["Drug: Memantine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive placebo(2 tab BID) for 7 days and continue placebo(1 tab BID) for 21 days.","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"Placebo","description":"Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks.","armGroupLabels":["Placebo"]},{"type":"DRUG","name":"Memantine","description":"Beside the usual treatment for ischemic stroke this group will be treated by memantine.","armGroupLabels":["Memantine"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Investigation of Neurological Deficit by National Institute of Health Scale Score (NIHSS)","description":"The National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS) is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0. Higher score is indicative of some level of impairment in neurological function.","timeFrame":"7 days"},{"measure":"Investigation of Disability by Modified Rankin Scale (mRS)","description":"The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability.\n\nThe scale runs from 0-6, running from perfect health without symptoms to death.\n\n0 - No symptoms.\n\n1. - No significant disability. Able to carry out all usual activities, despite some symptoms.\n2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.\n3. - Moderate disability. Requires some help, but able to walk unassisted.\n4. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.\n5. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.\n6. - Dead.","timeFrame":"7 days"}],"secondaryOutcomes":[{"measure":"Investigation of Neurological Deficit by National Institute of Health Scale Score (NIHSS)","description":"The National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS) is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0. Higher score is indicative of some level of impairment in neurological function.","timeFrame":"28 days"},{"measure":"Investigation of Disability by Modified Rankin Scale (mRS)","description":"The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability.\n\nThe scale runs from 0-6, running from perfect health without symptoms to death.\n\n0 - No symptoms.\n\n1. - No significant disability. Able to carry out all usual activities, despite some symptoms.\n2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.\n3. - Moderate disability. Requires some help, but able to walk unassisted.\n4. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.\n5. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.\n6. - Dead.","timeFrame":"28 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Presentation at first 24hrs of disease onset\n* Confirmation of ischemic stroke in MCA territory by imaging.\n* Accepted consent form\n\nExclusion Criteria:\n\n* Allergy history to memantine\n* Stage 4 -5 renal failure base on Acute Kidney Injury Network criteria\n* Moderate to severe hepatic failure (Child-Pugh criteria, grade B and C)\n* History of epilepsy\n* History of dementia\n* History of memantine use in recent 6 months\n* Pregnancy or breastfeeding\n* Severe drug adverse effects","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Memantine","description":"Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive 20 mg/d(2 tab 5mg BID) memantine for 7 days and then 10mg/d(1 tab 5mg BID) memantine for 21 days.\n\nMemantine: Beside the usual treatment for ischemic stroke this group will be treated by memantine."},{"id":"FG001","title":"Placebo","description":"Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive placebo(2 tab BID) for 7 days and continue placebo(1 tab BID) for 21 days.\n\nPlacebo: Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"20"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"20"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Memantine","description":"Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive 20 mg/d(2 tab 5mg BID) memantine for 7 days and then 10mg/d(1 tab 5mg BID) memantine for 21 days.\n\nMemantine: Beside the usual treatment for ischemic stroke this group will be treated by memantine."},{"id":"BG001","title":"Placebo","description":"Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive placebo(2 tab BID) for 7 days and continue placebo(1 tab BID) for 21 days.\n\nPlacebo: Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"47"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"18"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"29"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"71.56","spread":"13.03"},{"groupId":"BG001","value":"69.75","spread":"14.61"},{"groupId":"BG002","value":"70.79","spread":"13.6"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"21"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"26"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Iran","categories":[{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"47"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Investigation of Neurological Deficit by National Institute of Health Scale Score (NIHSS)","description":"The National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS) is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0. Higher score is indicative of some level of impairment in neurological function.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"7 days","groups":[{"id":"OG000","title":"Memantine","description":"Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive 20 mg/d(2 tab 5mg BID) memantine for 7 days and then 10mg/d(1 tab 5mg BID) memantine for 21 days.\n\nMemantine: Beside the usual treatment for ischemic stroke this group will be treated by memantine."},{"id":"OG001","title":"Placebo","description":"Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive placebo(2 tab BID) for 7 days and continue placebo(1 tab BID) for 21 days.\n\nPlacebo: Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.52","spread":"4.51"},{"groupId":"OG001","value":"5.75","spread":"4.94"}]}]}]},{"type":"PRIMARY","title":"Investigation of Disability by Modified Rankin Scale (mRS)","description":"The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability.\n\nThe scale runs from 0-6, running from perfect health without symptoms to death.\n\n0 - No symptoms.\n\n1. - No significant disability. Able to carry out all usual activities, despite some symptoms.\n2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.\n3. - Moderate disability. Requires some help, but able to walk unassisted.\n4. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.\n5. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.\n6. - Dead.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"7 days","groups":[{"id":"OG000","title":"Memantine","description":"Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive 20 mg/d(2 tab 5mg BID) memantine for 7 days and then 10mg/d(1 tab 5mg BID) memantine for 21 days.\n\nMemantine: Beside the usual treatment for ischemic stroke this group will be treated by memantine."},{"id":"OG001","title":"Placebo","description":"Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive placebo(2 tab BID) for 7 days and continue placebo(1 tab BID) for 21 days.\n\nPlacebo: Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.89","spread":"0.75"},{"groupId":"OG001","value":"2.55","spread":"1.19"}]}]}]},{"type":"SECONDARY","title":"Investigation of Neurological Deficit by National Institute of Health Scale Score (NIHSS)","description":"The National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS) is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0. Higher score is indicative of some level of impairment in neurological function.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"28 days","groups":[{"id":"OG000","title":"Memantine","description":"Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive 20 mg/d(2 tab 5mg BID) memantine for 7 days and then 10mg/d(1 tab 5mg BID) memantine for 21 days.\n\nMemantine: Beside the usual treatment for ischemic stroke this group will be treated by memantine."},{"id":"OG001","title":"Placebo","description":"Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive placebo(2 tab BID) for 7 days and continue placebo(1 tab BID) for 21 days.\n\nPlacebo: Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.42","spread":"2.96"},{"groupId":"OG001","value":"4.4","spread":"3.98"}]}]}]},{"type":"SECONDARY","title":"Investigation of Disability by Modified Rankin Scale (mRS)","description":"The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability.\n\nThe scale runs from 0-6, running from perfect health without symptoms to death.\n\n0 - No symptoms.\n\n1. - No significant disability. Able to carry out all usual activities, despite some symptoms.\n2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.\n3. - Moderate disability. Requires some help, but able to walk unassisted.\n4. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.\n5. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.\n6. - Dead.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"28 days","groups":[{"id":"OG000","title":"Memantine","description":"Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive 20 mg/d(2 tab 5mg BID) memantine for 7 days and then 10mg/d(1 tab 5mg BID) memantine for 21 days.\n\nMemantine: Beside the usual treatment for ischemic stroke this group will be treated by memantine."},{"id":"OG001","title":"Placebo","description":"Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive placebo(2 tab BID) for 7 days and continue placebo(1 tab BID) for 21 days.\n\nPlacebo: Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"0.95"},{"groupId":"OG001","value":"2.3","spread":"1.3"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"3 months","eventGroups":[{"id":"EG000","title":"Memantine","description":"Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive 20 mg/d(2 tab 5mg BID) memantine for 7 days and then 10mg/d(1 tab 5mg BID) memantine for 21 days.\n\nMemantine: Beside the usual treatment for ischemic stroke this group will be treated by memantine.","deathsNumAffected":0,"deathsNumAtRisk":27,"seriousNumAffected":0,"seriousNumAtRisk":27,"otherNumAffected":0,"otherNumAtRisk":27},{"id":"EG001","title":"Placebo","description":"Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive placebo(2 tab BID) for 7 days and continue placebo(1 tab BID) for 21 days.\n\nPlacebo: Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks.","deathsNumAffected":0,"deathsNumAtRisk":20,"seriousNumAffected":0,"seriousNumAtRisk":20,"otherNumAffected":0,"otherNumAtRisk":20}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Nasim Tabrizi","organization":"Mazandaran University of medical sciences","email":"nasimtabrizi@gmail.com","phone":"+981133343015"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000020521","term":"Stroke"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000008559","term":"Memantine"}],"ancestors":[{"id":"D000000978","term":"Antiparkinson Agents"},{"id":"D000018726","term":"Anti-Dyskinesia Agents"},{"id":"D000015259","term":"Dopamine Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000018691","term":"Excitatory Amino Acid Antagonists"},{"id":"D000018683","term":"Excitatory Amino Acid Agents"}],"browseLeaves":[{"id":"M11232","name":"Memantine","asFound":"Ophthalmic Solution","relevance":"HIGH"},{"id":"M3985","name":"Antiparkinson Agents","relevance":"LOW"},{"id":"M7163","name":"Dopamine","relevance":"LOW"},{"id":"M17652","name":"Dopamine Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"},{"id":"M20461","name":"Excitatory Amino Acid Antagonists","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnDyAg","name":"Anti-Dyskinesia Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"CaAg","name":"Cardiotonic Agents"}]}},"hasResults":true}